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Background: Patient adherence to recommended use of ICS is questionable in asthma, with
irregular use or interruptions occurring frequently. Factors explaining discontinuation of
controller therapy could orientate interventions. The characteristics of patients with interrup-
tions of inhaled corticosteroids (ICSs), intentional or accidental, were investigated.
Methods: Asthma patients regularly prescribed ICS by GPs (Cegedim network) were included.
Patients’ characteristics and behaviours toward ICS (accidental/intentional interruptions, less
frequent use of ICS and change in dosing) were identified from self-report questionnaires, and
linked to data prescription database. Interrelations between declared behaviours toward ICS
were studied with a Multiple Component Analysis (MCA) and the correlates of ICS interruptions
were identified.
Results: During the past 3 months, 31.6% of 204 patients (mean age: 53.8 years, females:
59.3%) intentionally interrupted ICS when feeling better, 25.4% forgot ICS and 18.3% deliber-
ately changed the doses. A quarter of patients considered constant use of respiratory medi-
cines as unhealthy. MCA revealed that intentional, accidental interruptions and less
frequent use of ICS were closely correlated. Risk of intentional interruption was increased
when patients considered constant use of respiratory therapy to be unhealthy (ORZ 3.36,
95%CIZ [1.47e7.66]). Conversely, risk was significantly lower when ICS was associated or
combined with another controller (ORZ 0.24, 95%CIZ [0.08e0.73]), compared to ICS ineuro-e´pide´miologie et de Pharmaco-e´pide´miologie, Hoˆpital Neurologique Pierre Wertheimer, 59
France. Tel.: þ33 (0) 472 129 709; fax: þ33 (0) 472 129 714.
u-lyon.fr (E. Van Ganse).
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Behaviours toward controller therapy in asthma 1367monotherapy. Less frequent interruptions were observed in patients older than 65 (ORZ 0.35,
95%CIZ [0.13e0.89]).
Conclusions: Our study suggests that discontinuation of use of controllers is associated with
other inadequate behaviours or beliefs about inhaled controllers. Efforts should be targeted
at patients’ perceptions and behaviours toward controller therapy.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
The detrimental effects of asthma on patients’ quality of life1
and medical resource utilization2 have been highlighted. The
quality of asthma management remains an essential issue.3
Adherence to inhaled corticosteroids therapy (ICS) is a major
objective in asthma care. A critical step to improve adherence
is to understand patients’ beliefs and behaviours toward their
inhaled anti-inflammatory therapy.
Guidelines recommend daily and regular use of inhaled
anti-inflammatory therapy for patients with persistent
asthma.4 Nonetheless, in real medical practice, many
studies have highlighted patients’ inadequate adherence to
inhaled corticosteroids.5,6
Adherence covers successive levels from drug prescription
and dispensing up to the actual use by the patients.7 As
a consequence, being prescribed ICS on a regular basis is not
a sufficient evidence of satisfactory quality of asthma care,
and a more comprehensive understanding of patients’
behaviours toward controllers in actual condition of use,
which includes intentional or accidental interruptions and
changing of doses, is needed. Also, the characteristics of non-
adherent patients have been inadequately explored in
patients regularly followed and treated for asthma. Besides, it
would be of interest to verify to which extent the different
behaviours reflecting inadequate adherence are correlated.
In a population of asthma patients receiving ICS, alone
or together with other controllers, we examined declared
behaviours toward ICS therapy, as approached by different
behaviours toward ICS therapy.Methods
Study design and study population
A cross-sectional observational study was conducted in
primary care (2004e2005) among asthma patients, aged 15
or more, supervised by GPs members of CEGEDIM network.
This network includes a nationwide representative sample
of French GPs who participate to a computerized prescrip-
tion database. Only patients regularly followed (two or more
visits during the past 12 months) and with at least one
prescription of ICS (alone or combined with acting beta
agonist) during the past 6 months before the study were
eligible. Additionally, when this ICS prescription was recent
(at inclusion or within the 3 preceding months), the presence
of a former one in the database was requested in order to
avoid newly treated patients. Patients were excluded in
case of associated COPD diagnosis or language/under-
standing problems. Patients who met inclusion criteria were
recruited when they visited their GP. After explanation ofthe study, patients who agreed to participate were included.
The protocol of the study was approved by the French Data
Protection Authority.
Data collected
Data were obtained from self-reported questionnaires
completed at inclusion visit and a computerized prescrip-
tion database.
Patients’ characteristics and factors related to
asthma
Patient questionnaires reported sociodemographic data and
quality of life (QVSA).8 QVSA score ranged from 0% to 100%
(optimal quality of life). The Asthma Control Test was used
to assess the level of asthma control. It was coded as
correct vs. inadequate control with the Sum score method.9
Patients’ behaviours toward asthma controller
therapy
Patients reported in questionnaires how they behaved
toward their inhaled controller therapy during the 3 months
before inclusion. Six non-exclusive declared behaviours
toward ICS were investigated: (1) accidental interruption,
(2) intentional interruption when feeling better, (3) inten-
tional interruption when feeling worse, (4) reduced use when
feeling better, (5) more frequent use of ICS in case of
preliminary signs of asthma attack and (6) intentional
changes of doses, independently of physician. The reference
for reduced use and more frequent use was the frequency
prescribed by the physician. Patients also mentioned
whether they considered constant use of respiratory drugs as
unhealthy. The corresponding variables (except intentional
changes of doses) were coded with a Likert-scale (never/
scarcely/sometimes/often/very often).
Prescribed asthma therapy
Asthma therapy was obtained from the prescription comput-
erized database. It consisted of controllers and rescue medi-
cations (short-acting beta agonists and anticholinergic drugs).
Controller medication classes included inhaled corticoste-
roids (ICS), long-acting beta agonists (LABA), LABAeICS fixed
combinations, oral beta agonists, oral xanthine, leukotriene
receptor antagonists (LTRA). Controller regimens were clas-
sified as follows: ICS only, ICS and LABA (as separate medica-
tions), combined LABAeICS alone, combined LABAeICS with
other controllers and other associations of controllers. The
average daily dose of prescribed ICS (Beclomethasone
1368 L. Laforest et al.dipropionate equivalent) was computed during the 6 months
before index date. Based on GINA criteria, these doses were
considered as high, medium or high (500, >500e1000,
>1000 mg/d, Beclomethasone equipotent respectively).4
Analyses
Patients’ characteristics and self-reported behaviours
toward ICS
Overall 204 patients were eligible and no newly treated
patient was identified among them.
First, patients disease characteristics and prescribed
therapy were studied. Then, patients’ reported behaviours
toward ICS and belief about regular use of ICS were described.
A multiple component analysis (MCA) was performed
with these variables to ascertain to which extent they were
altogether associated. Given the limited counts, available
items ‘never’ and ‘scarcely’ on one hand, and ‘sometimes’,
‘often’ and ‘very often’ on the other hand, were pooled
together as in prior analyses.
Correlates of accidental and intentional interruption
of ICS
Inferential analyses focused specifically on accidental and
intentional (when feeling better) interruptions of ICS
(‘sometimes or more’ vs. ‘never/scarcely’). Both variables
were studied according to patients’ characteristics, asthma
control and asthma therapy. Chi-Square test and Wilcoxon
ranked test were used for univariate analyses.
Multivariate logistic regression models were computed.
The risks of accidental and intentional interruption of ICS
therapy (sometimes or more) were studied, respectively.
Both models systematically included age, gender, asthma
control, use of oral corticosteroid burst and asthma
controller regimens (with ICS monotherapy as reference).
Other factors were included in the model when they
showed a significant univariate association with the studied
variable (p< 0.10). The variables referring to declared
behaviours to ICS were not entered into models as they
were not considered as explanatory factors.
Results
Patients’ characteristics (Table 1)
Patients were included from May 2004 until July 2005. Mean
age of the 204 patients who completed questionnaires was
53.8 years (SDZ 19.6), with 59.3% females, 13.7% were
smokers. During the 6 months before the survey, most
patients received combined LABAeICS alone (39.2%) or with
another controller (24.5%). Other categories were ICS mon-
otherapy (12.3%), ICS and LABA in two separate drugs
(14.2%), and other regimens (9.8%). The ‘Other regimens’
category consisted of ICSþ LABAþ LTRA (nZ 8), ICSþ oral
beta agonist (nZ 3), ICSþ oral xanthine (nZ 3), ICSþ LTRA
(nZ 2), ICSþ LABAþ oral xanthine (nZ 2), ICSþ oral
xanthineþ oral beta agonist (nZ 1) and ICSþ LTRAþ
LABAþ oral beta agonist (nZ 1).
During the 6 months, 21.1%, 44.6% and 34.3% of patients
received low, medium, and high daily equipotent doses of
ICS, respectively.Nearly half the patients were prescribed short-acting
beta agonists (SABA, 51.5%). Few received SABA with anti-
cholinergic drugs combined or not with SABA (6.9%). A
minority of patients (12.4%) reported the use of oral or
injected corticosteroids during the past 3 months. Based on
the Asthma Control Test score, about 40% of patients were
inadequately controlled. QVSA score ranged from 8.3 to
98.3%, with a mean value at 58.4% (SDZ 17.8%).
Patients’ reported behaviours toward ICS therapy
(past 3 months)
Descriptive analyses
Interruptions of ICS were commonly reported. Nearly one-
third of patients reported intentional interruptions while
a quarter of them omitted ICS therapy (Table 1). So was
patients’ less frequent use or intentional interruption of ICS
when feeling better. About, 5% interrupted ICS when
feeling worse. Nearly one patient in four believed that
constant use of respiratory drug was unhealthy (Table 1),
and about one patient in five spontaneously changed dosing
during the past 3 months. These changes mainly consisted
of reducing ICS doses. A more frequent use of ICS in the
case of preliminary signs of asthma attacks was only
reported by about 20% of patients.
Associations between behaviours toward ICS
Multiple component analyses conducted on the 204
patients suggested that the three behaviours resulting in
a lower use of ICS (accidental interruption, intentional
interruption, less frequent use when feeling better) were
all closely associated (Fig. 1). These three behaviours
appeared correlated with the belief that constant use of
respiratory drugs was unhealthy. Conversely, changing of
doses and increasing doses in case of signs of asthma
attacks seemed more independent from the latter
variables (Fig. 1). Most of these findings were confirmed in
univariate analyses (Table 2). Interruption of ICS when
feeling worse was not included in the multiple component
analysis given its low frequency.
Correlates of intentional and accidental
interruptions of ICS therapy (past 3 months
before inclusion)
Univariate analyses
More than twofold higher rates of interruptions (intentional
or accidental) were observed among patients aged 45 or
less compared to their counterparts older than 65 (Table 2).
Despite the absence of global significant difference in ICS
interruption between the different types of controller
regimens, higher rates of interruptions (intentional or
accidental) were observed in the ICS monotherapy cate-
gory. Patients who considered constant use of respiratory
drugs as unhealthy were more likely to interrupt inten-
tionally or accidentally their ICS therapy (Table 2).
Conversely, no effect of the daily dose of ICS was observed.
No significant association was observed between ICS
interruption and gender, use of oral or injected cortico-
steroid course, intensity of ICS therapy, smoking status,
asthma control or quality of life (Table 2).
Table 1 Characteristics of the study population.
Overall n, %
204 100





Current smoking 28 13.7
Asthma severity (nZ 193)
No oral or injected corticosteroid course (past 3 months) 169 87.6
At least one oral or injected corticosteroid course (past 3 months) 24 12.4
Average daily doses of prescribed ICSa (past 6 months)
500 mg/d 43 21.1
>500e1000 mg/d 91 44.6
>1000 mg/d 70 34.3
Inadequate asthma control (Asthma Control Test) 76 39.8
Correct asthma control 115 60.2




Controller regimens (past 6 months)
Inhaled corticosteroids (ICS) alone 25 12.3
ICSþ long-acting beta agonist (two separate drugs) 29 14.2
Combined ICS long-acting beta agonist alone 80 39.2
Combined ICS long-acting beta agonist with other controllers 50 24.5
Other regimens 20 9.8
Short-acting beta agonists (SABA) 99 48.5
Anticholinergic or SABA-anticholinergic 14 6.9
Patients’ behaviours and beliefs toward controller therapy
Believing that continuous use of respiratory drugs is unhealthyc 44 23.7
Self-reported behaviours during the past 3 months
Accidental interruption of ICS
Never/scarcely 138 74.6
Sometimes/often/very often 47 25.4
Intentional interruption of ICS when feeling better
Never/scarcely 128 68.4
Sometimes/often/very often 59 31.6
Intentional interruption of ICS when feeling worse
Never/scarcely 176 94.6
Sometimes/often/very often 10 5.4
Less frequent use of ICS when feeling better
Never/scarcely 136 68.7
Sometimes/often/very often 62 31.3
More frequent use of ICS in case of premonitory signs of asthma attack
Never/scarcely 156 78.8
Sometimes/often/very often 42 21.2
(continued on next page)
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Table 1 (continued )
Overall n, %
204 100




a Beclomethasone equivalent doses.
b Dichotomised according to tertile values.
c Out of 186 patients.
d Out of 191 patients.
1370 L. Laforest et al.Multivariate models
Multivariate models confirmed most univariate findings.
Significantly decreased risks of intentional and accidental
interruptions were observed for older patients. Patients’
belief that continuous use of asthma therapy was
unhealthy which was a prominent predictor of both
outcomes (Table 3).
Compared to patients under ICS monotherapy, those who
received additional controller(s), or combined LABAeICS
therapy exhibited lower risk of intentional interruption
(Table 3).When all the categories ofpatients who received ICS
and another controller (combined or concurrent drugs) were
merged, a significantly decreased riskwasobservedcompared
to ICS monotherapy (ORZ 0.24, 95%CIZ [0.08e0.73]). In
contrast, the corresponding risk was not significant for acci-
dental ICS interruption: ORZ 0.38, 95%CIZ [0.13e1.17].Figure 1 Patients’ self-reported behaviours and beliefs toward
component analysis).Discussion
In this population of asthma patients treated with inhaled
corticosteroids (ICS) in primary care, self-reported adher-
ence to controllers was far from optimal. Interruptions and
changes of doses were common. Most misbehaviours toward
ICS were closely correlated and ICS interruptions were also
associated with patients’ belief that continuous use of
respiratory drug is harmful. Accidental and intentional
interruptions of ICS treatment also decreased with age and
when another controller was associated with ICS (Table 2).
Patients’ behaviours toward ICS therapy
During the past 3 months, interruptions of ICS were
common in this population of regularly followed asthmaICS therapy during the 3 months preceding inclusion (Multiple
Table 2 Intentional and accidental ICS interruptions (sometimes or more) according to patients’ characteristics and asthma





Total count % ‘Sometimes
or more’
Pa Total count % ‘Sometimes
or more’
Pa
Overall 187 31.5 e 185 25.4 e
Gender
Female 106 32.1 0.86 105 26.7 0.65
Male 81 30.9 80 23.7
Age (years)
15e45 66 43.9 0.007 65 40.0 0.0035
46e65 60 31.7 60 18.3
>65 61 18.0 60 16.7
Smoking status
Current smoking 28 39.3 0.34 28 25.0 0.96
No smokers 159 30.2 157 25.5
Asthma severity (past 3 months)
No oral or injected
corticosteroid course
159 33.3 0.57 157 25.5 0.86
At least one oral or injected
corticosteroid course
22 27.3 22 27.3
Average daily doses of prescribed ICSb (past 6 months)
500 mg/d 43 41.9 0.15 42 33.3 0.28
>500e1000 mg/d 80 25.0 79 20.2
>1000 mg/d 64 32.8 64 26.6
Asthma control level (Asthma Control Test)
Inadequate 71 32.4 0.83 70 30.0 0.21
Correct 107 30.8 106 21.7
Controller regimens (past 6 months) 0.13 0.57
Inhaled corticosteroids alone 22 45.4 22 31.8
CIþ long-acting Beta Agonist
(two separate drugs)
28 28.6 28 21.4
Combined CI long-acting beta
agonist alone
76 28.9 75 25.3
Combined CI long-acting beta
agonist with other controllers
43 39.5 43 30.2
Other regimens 18 11.1 17 11.8
Short-acting beta agonists 93 28.0 0.29 93 22.6 0.37
Anticholinergic or SABA-anticholinergic 13 30.8 1.00 12 16.7 0.37
Declared behaviours toward ICS
Intentional interruption of ICS when
feeling better
<0.0001
Never/scarcely e 128 7.8
Sometimes/often/very often e 57 64.9
Intentional interruption of ICS when
feeling worse
0.0007 0.0002
Never/scarcely 176 29.0 175 22.9
Sometimes/often/very often 10 80.0 9 77.8
Less frequent use of ICS when
feeling better
<0.0001 <0.0001
Never/scarcely 130 14.6 129 12.4
Sometimes/often/very often 56 71.4 55 56.4
(continued on next page)
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Total count % ‘Sometimes
or more’
Pa Total count % ‘Sometimes
or more’
Pa
More frequent use of ICS in case of
premonitory signs of asthma attack
0.67 0.06
Never/scarcely 147 30.6 145 22.1
Sometimes/often/very often 38 34.2 38 36.8
Intentional change in the dosing
of ICS
<0.0001 0.0001
Yes 35 65.7 35 51.4
No 150 24.0 148 19.6
Belief that continuous use of respiratory drugs is unhealthy
Yes 41 51.2 0.002 40 42.5 0.008
No 140 25.7 139 21.6
Global QVSA score 0.80 0.92
<52 53 32.1 51 25.5
53e66 52 32.7 52 28.8
>66 53 37.7 53 26.4
a Difference between patients who interrupted therapy sometimes or more often and the other patients.
b Beclomethasone equivalent dose.
1372 L. Laforest et al.patients. So was the belief that there was a risk for health
through continuous use of respiratory drugs (Table 1).
Intentional and accidental non-adherence with ICS have
been commonly described in asthma by previous studies.10
More specifically, lack of perceived symptoms by patients
(‘no symptom no asthma’) has been found as a major
cause of patients’ intentional interruption of ICS.11,12 The
absence of immediate perceived relief with ICS (except for
combined LABAeICS therapy) may contribute to this inad-
equate use.
In addition, patients’ misuse of ICS may also result from
a misunderstanding about their exact role in asthma
therapy,13 fear of addiction14 and of potential side
effects.13,14 As well, the necessity of daily use of ICS may
not always be understood by patients.12 Our data illus-
trated the common occurrence of prejudices about respi-
ratory therapy (Table 1). Moreover, the relationship
between such misperception of respiratory therapy and ICS
misuse was clearly illustrated (Table 3).
Changes of ICS doses were also common (Table 1) and
mostly consisted of reducing doses. However, interpreting
these results may be difficult. First, patients’ spontaneous
increase and decrease of dose may correspond to distinct
therapybehaviour patterns.Unfortunately, countsofpatients
who only increased ICS doses were too limited for meaningful
analyses. Moreover, patients’ spontaneous change in ICS dose
may be considered as positive, provided that it is in accor-
dance with care-giver directions and/or asthma plans.
Only 20% of patients used ICS therapy more frequently in
the case of preliminary signs of asthma attacks. This inad-
equate proportion could be explained by a higher use of
rescue medication for asthma attack, at the expense of
increasing inhaled anti-inflammatory therapy.10,15Associations of the different behaviours
toward ICS therapy
The strong correlations observed between ICS intentional
interruption, less frequent use when feeling better and
accidental interruption suggest that under-users of ICS may
correspond to a unique profile of patients. Conversely,
changes of doses and, more specifically, more frequent use
of ICS therapy in case of attacks appeared less correlated
with under-use of ICS (Table 2). These findings were illus-
trated by the multiple component analysis (Fig. 1).
Patients’ perception of constant use of respiratory
drugs as unhealthy was a major predictor of ICS interrup-
tion. Horne et al. found a stronger influence of medica-
tions’ beliefs about adherence, compared to personal or
clinical factors.16 This association may reflect fear of
adverse events or overdosing and would deserve further
investigation.
This finding is of concern as it strongly suggests that an
erroneous perception of asthma therapy may lead to an
under-use of controllers, whether intentional or not.
Indeed, higher adherence to asthma therapy has been
shown to be associated with patients’ stronger beliefs in
the benefits of the treatments.10,17
Other correlates of ICS interruption (intentional
and accidental)
Significantly fewer ICS interruptions were observed in older
asthma patients (Tables 2, 3). A better adherence to ICS in
older asthma patients has been reported,16,18 although
other studies did not confirm this result.19,20
Table 3 Logistic models, risks of intentional (Model 1) and accidental interruption of ICS (Model 2).
OR 95%CI






Male gender 1.00 0.48e2.01
At least one oral or injected corticosteroid course (past 3 months) 0.75 0.22e2.58
Inadequate asthma control 0.93 0.41e2.09
Controller regimens (past 6 months)
ICS alone Ref e
ICSþ Long-acting beta agonist (two separate drugs) 0.21 0.05e0.85
Combined ICS Long-acting beta agonist alone 0.27 0.09e0.85
Combined ICS Long-acting beta agonist with other controllers 0.36 0.10e1.23
Other regimens 0.08 0.01e0.50
Belief that continuous use of respiratory drugs is unhealthy 3.36 1.47e7.66





Male gender 0.79 0.36e1.73
At least one oral or injected corticosteroid course (past 3 months) 0.88 0.26e3.06
Inadequate asthma control 1.36 0.59e3.12
Controller regimens (past 6 months)
ICS alone Ref. e
ICSþ long-acting beta agonist (two separate drugs) 0.30 0.07e1.29
Combined ICS long-acting beta agonist alone 0.40 0.12e1.31
Combined ICS long-acting beta agonist with other controllers 0.52 0.15e1.85
Other regimens 0.15 0.02e0.97
Belief that continuous use of respiratory drugs is unhealthy 2.53 1.08e5.91
Behaviours toward controller therapy in asthma 1373Patients who received another controller in addition to
ICS e combined or concurrent drug e were less likely to
intentionally interrupt ICS. Most of the 179 regimens with at
least one controller in addition to ICS included a LABA
(nZ 170). The beneficial impact adjunction of LABA to ICS on
asthma control has been demonstrated.21,22 Patients who
perceive the broncho-dilatation physiological effects of the
beta agonist may be more prone to regular use of their
asthma drugs. Conversely, no difference in interruption rates
appeared between patients under combined LABAeICS
therapy and those with twoconcurrent controllers, whichare
not in line with the conclusions of previous studies: better
adherence rates with combined LABAeICS therapy compared
to concurrent therapy have been reported.23,24 Interpreting
the observed differences in adherence patterns according to
the type of controller therapy requires caution. First, our
study explored only some dimensions of adherence. As
a consequence, no conclusion can be drawn with regard to
adherence as an overall outcome. Then, our number of
patients under isolated ICS therapy was limited. Hence,a confirmation on a higher number of patients is desirable.
Last, our observational study did not provide a level of
evidence similar to those of randomised trials. In contrast, no
association emerged between ICS interruptions, the use of
oral or injected corticosteroids, the intensity of prescribed
therapy, and more surprisingly asthma control. The detri-
mental impact of inadequate ICS use on asthma control has
been established.6 Our assessment of ICS use without precise
dates of interruptions was a limitation to examining in detail
the effects on asthma control with a detailed temporality.
Nevertheless, this unexpected finding should be interpreted
with care and requires confirmation in further studies.
This study had other limitations. Due to the low counts
of patients, the different items of the semi quantitative
Likert-scale of declared behaviours (‘never’ to ‘very often’)
were merged into two categories (‘never’ or ‘scarcely’ vs.
‘sometimes’ or ‘more often’), which prevented more
accurate analyses. Also, behaviours toward ICS therapy
were retrospectively self-reported by patients, which could
lead to under-assessment of treatment omission due to
Ethics statement
The protocol of the study was approved by the French Data
Protection Authority. This study was purely observational
(patients’ management was not affected by the study).
1374 L. Laforest et al.memory bias. Nonetheless, these behaviours were
estimated only during 3 months in order to limit this
risk. Lastly, despite such potential bias, high rates of
self-reported misbehaviours were still observed. Our study
was conducted in a selected sample of asthma patients
receiving ICS, who volunteered to participate. As a conse-
quence, worse results could be expected in a more general
population of asthma patients. Lastly, education level,25
psychological factors26 or duration of asthma17 that may
potentially influence adherence to controllers were not
documented.
Our data are of concern as they underline the inade-
quate adherence to ICS, even in a selected population of
regularly treated asthma patients. In addition to the
detrimental consequences on health and quality of life,
under-use of ICS, along with an overuse of rescue medi-
cation, may result in a higher use of medical care
resources.27
The precise reasons why patients purposely under-use
or forget ICS therapy should be more thoroughly investi-
gated. Our data advocate the need for better education
for asthma patients, most particularly on the role of ICS in
asthma therapy. Notably, potential prejudices toward
controllers should be better addressed to effectively
correct them.13 As underlined by Horne, failure to adhere
to chronic therapy is correlated with patients’ doubts
about personal need for medication and fear of adverse
effects.16 Hence, the rationale of the regular use of ICS
requires the understanding by patients of asthma as
a chronic disease, even in the absence of overt
symptoms.14
A better communication between care-givers and
patients, and more efficient involvement of patients in the
management of their disease are also highly desirable.
Patients are more likely to report regular use of ICS if they
see themselves as active participants in disease manage-
ment.11,28 Specific attention should be directed to patients
under 45, whose adherence seems less adequate.
In conclusion, the irregular use of ICS in this population
of treated asthma patients is of concern. This underlines
the urgent need to better educate patients about inhaled
anti-inflammatory therapy in asthma.Acknowledgments
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